Prevalence and Pattern of Adverse Events Following COVID-19 Vaccination Among Adult Population in Sokoto Metropolis, Northwest, Nigeria

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2025 Mar 12

PMID 40073304

Authors

Habibullah Adamu

Sufyanu Lawal

Ishaka Alhaji Bawa

Akilu Muhammad Sani

Adamu Ahmed Adamu

Affiliations

Soon will be listed here.

Abstract

Background: COVID-19 still poses a major public health challenge worldwide and vaccination remains one of the major interventions to control the disease. Different types of vaccines approved by the World Health Organization (WHO) are currently in use across the world to protect against the disease. This study assessed the prevalence and pattern of adverse events following immunization (AEFI) after receiving COVID-19 vaccine (the Oxford-AstraZeneca vaccine) among the adult population in Sokoto metropolis, North-west, Nigeria.

Methods: We conducted a cross-sectional study among 230 adults in Sokoto metropolis who received COVID-19 vaccines. Data was collected using a structured questionnaire administered via personal phone calls to respondents who were selected via a systematic sampling technique. For data analysis, IBM SPSS version 25.0 was used.

Results: The majority of the participants [183 (79.7%)] experienced AEFI. The most common adverse events were body weakness [157 (85%)], fever [111 (60.3%)] and headache [103 (56%)]. Up to half of the respondents that experienced AEFI said it occurred within minutes and a few hours, whereas 75 (40.8%) said it was within 2-3 days. Up to 66.3% of the adverse reactions were mild and lasted between a few hours (37.5%) and one day (31.5%); however, 15.2% of the respondents had severe reactions of which 22.7% were admitted to a health facility. The development of AEFI was linked to the presence of an underlying medical condition (p = 0.001), a previous history of AEFI (p = 0.017), and a history of drug reaction (p = 0.005).

Conclusion: The majority of respondents reported adverse events following vaccination with the Oxford-AstraZeneca vaccine; body weakness, fever, and headache being the most common AEFIs. History of underlying medical condition as well as a history of adverse drug reactions were predictors of the development of adverse reactions following COVID-19 vaccination. Service providers at each COVID-19 vaccination point should always take the time to explain to vaccine recipients that adverse reactions are possible; however, they should reassure them that most ARs resolve within a few hours to a few days.

References

Yap C, Ali A, Prabhakar A, Prabhakar A, Pal A, Lim Y . Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. Ther Adv Vaccines Immunother. 2021; 9:25151355211059791. PMC: 8637774. DOI: 10.1177/25151355211059791. View

Parida S, Sahu D, Singh A, Alekhya G, Subba S, Mishra A . Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol. 2022; 94(6):2453-2459. PMC: 9088522. DOI: 10.1002/jmv.27655. View

Kim S, Wi Y, Yun S, Ryu J, Shin J, Lee E . Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. J Korean Med Sci. 2021; 36(14):e107. PMC: 8042479. DOI: 10.3346/jkms.2021.36.e107. View

Konu Y, Gbeasor-Komlanvi F, Yerima M, Sadio A, Tchankoni M, Zida-Compaore W . Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021. Arch Public Health. 2021; 79(1):207. PMC: 8611394. DOI: 10.1186/s13690-021-00741-x. View

Jamshidi E, Asgary A, Yazdizadeh Kharrazi A, Tavakoli N, Zali A, Mehrazi M . Personalized predictions of adverse side effects of the COVID-19 vaccines. Heliyon. 2023; 9(1):e12753. PMC: 9800018. DOI: 10.1016/j.heliyon.2022.e12753. View

Dziedzic A, Riad A, Attia S, Klugar M, Tanasiewicz M . Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe. J Clin Med. 2021; 10(22). PMC: 8623766. DOI: 10.3390/jcm10225338. View

Bae S, Lee Y, Lim S, Lee J, Lim J, Lee S . Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. J Korean Med Sci. 2021; 36(17):e115. PMC: 8093607. DOI: 10.3346/jkms.2021.36.e115. View

Thomas S, Moreira Jr E, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 385(19):1761-1773. PMC: 8461570. DOI: 10.1056/NEJMoa2110345. View

Tran V, Nguyen H, Le T, Truong T, Nguyen P, Thu Hoai Nguyen T . Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021. Vaccine. 2021; 39(44):6485-6491. PMC: 8485226. DOI: 10.1016/j.vaccine.2021.09.060. View

10.

Karafillakis E, Larson H . The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine. 2017; 35(37):4840-4850. DOI: 10.1016/j.vaccine.2017.07.061. View

11.

Granados Villalpando J, de Jesus Romero Tapia S, Baeza Flores G, Ble Castillo J, Juarez Rojop I, Lopez Junco F . Prevalence and Risk Factors of Adverse Effects and Allergic Reactions after COVID-19 Vaccines in a Mexican Population: An Analytical Cross-Sectional Study. Vaccines (Basel). 2022; 10(12). PMC: 9781330. DOI: 10.3390/vaccines10122012. View

12.

Bujang M . A Step-by-Step Process on Sample Size Determination for Medical Research. Malays J Med Sci. 2021; 28(2):15-27. PMC: 8075593. DOI: 10.21315/mjms2021.28.2.2. View

13.

Xing K, Tu X, Liu M, Liang Z, Chen J, Li J . Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021; 23(3):221-228. PMC: 7969187. View

14.

Helmy Y, Fawzy M, Elaswad A, Sobieh A, Kenney S, Shehata A . The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. J Clin Med. 2020; 9(4). PMC: 7230578. DOI: 10.3390/jcm9041225. View

15.

Lee S, Lee H, Lee S, Moon J, Moon S, Chung S . Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2. Front Med (Lausanne). 2021; 8:738049. PMC: 8514770. DOI: 10.3389/fmed.2021.738049. View

16.

Anjorin A, Odetokun I, Nyandwi J, Elnadi H, Awiagah K, Eyedo J . Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa. Vaccines (Basel). 2022; 10(4). PMC: 9032114. DOI: 10.3390/vaccines10040546. View

17.

Herve C, Laupeze B, Del Giudice G, Didierlaurent A, Da Silva F . The how's and what's of vaccine reactogenicity. NPJ Vaccines. 2019; 4:39. PMC: 6760227. DOI: 10.1038/s41541-019-0132-6. View

18.

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

19.

Riad A, Pokorna A, Attia S, Klugarova J, Koscik M, Klugar M . Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med. 2021; 10(7). PMC: 8037149. DOI: 10.3390/jcm10071428. View

20.

Mascellino M, Di Timoteo F, De Angelis M, Oliva A . Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infect Drug Resist. 2021; 14:3459-3476. PMC: 8418359. DOI: 10.2147/IDR.S315727. View